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Summary
Objectives:  Ondansetron  is  an  antiemetic  5-HT3  receptor  antagonist  with  proven  efﬁcacy  in
central balance  disorder.  A  pilot  study  investigated  impact  on  acute  unilateral  vestibular  neu-
ritis.
Patients and  methods:  A  randomized  clinical  trial  included  20  vestibular  neuritis  patients.
Subjects received  methylprednisolone-valacyclovir,  associated  to  5  days’  metoclopramide
(30 mg/d;  group  M,  n  =  10)  or  ondansetron  (8  mg/d;  group  O,  n  =  10).  Assessment  was  based
on early  and  1  month  videonystagmography,  duration  of  hospital  stay  and  time  to  ﬁrst  indepen-
dent walking.  Blinded  intention-to-treat  analysis  used  univariate  (Student  test)  and  multivariate
(linear logistic  regression)  analysis.
Results:  Early  caloric  vestibular  deﬁcit  was  signiﬁcantly  lower  in  group  O  than  group  M  (56.53%
versus 84.38%;  P  =  0.03).  Vestibular  preponderance  did  not  differ  between  groups  (8.2◦/s  in  O
versus 10.34◦/s  in  M).  At  1  month,  trends  were  observed  for  vestibular  deﬁcit  (43%  in  O  versus
63.4% in  M;  P  =  0.07)  and  preponderance  (1.67◦/s  in  O  versus  1.74◦/s  in  M;  P  =  0.4).  Hospital
stay and  time  to  ﬁrst  independent  walking  were  signiﬁcantly  shorter  in  O  (2.88  versus  4.5  days
(P =  0.03);  and  1.25  versus  2.25  days  (P  =  0.001),  respectively).
Conclusion:  Early  treatment  with  ondansetron  associated  to  corticosteroids  and  antiviral  treat-
ment reduced  vestibular  deﬁcit  in  acute-phase  vestibular  neuritis  as  compared  to  reference
histamine H1  receptor  antagoni
eﬁt includes  improved  tolerance
should be  conﬁrmed  on  a  larger
5-HT3 antagonists  on  vestibular  
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he  physiopathology  of  vestibular  neuritis  is  poorly  under-
tood;  viral  infection  and/or  microcirculation  disorder  are
urrently  the  main  hypotheses  [1].  Whatever  the  mecha-
ism,  it  induces  neuronal  dysfunction  in  Scarpa’s  ganglion
r  the  brainstem  [2].
The  usual  antiemetics  prescribed  to  treat  the  associ-
ted  vegetative  signs  are  histamine  H1  receptor  antagonists.
part  from  their  antiemetic  effect,  these  receptors  have
een  shown  to  be  present  on  and  affect  the  function  of
estibular  neurons  [3].  H1  antagonists  may  thus  play  a  role
n  vestibular  function  as  such  [4].
More  recently,  other  antiemetics,  serotonin  5-HT3  recep-
or  antagonists,  were  used  in  nausea  and  vomiting,  being
ore  effective  than  H1  antagonists.  In  animals,  5-HT3  recep-
ors  are  expressed  in  the  neurons  of  Scarpa’s  ganglion  and
edial  brainstem  vestibular  nuclei  [5].  We  therefore  sought
o  investigate  their  as  yet  undetermined  role  in  regulating
estibular  physiology.
Given  the  proven  efﬁcacy  of  5-HT3  receptors  in  post-
raumatic  neuroprotection  [6],  the  present  pilot  study
ocused  on  the  preventive  effect  of  a  5-HT3  antagonist,
ndansetron,  on  vestibular  deﬁcit  in  acute-phase  vestibular
euritis.
atients and methods
n  open-label,  randomized  comparative  study  was  con-
ucted  within  the  ENT  department  of  the  Montpellier
France)  University  Hospital  Center  from  September  2007  to
ecember  2008.  The  study  drugs  were  already  authorized  for
he  indication  in  question;  local  ethics  committee  approval
as  obtained.
All  cases  (n  =  34)  of  suspected  vestibular  neuritis  with
nset  at  least  48  hours  before  initiation  of  treatment  were
ncluded.  In  case  of  misdiagnosis  corrected  on  videonystag-
ography  (VNG:  central  signs  or  less  than  25%  deﬁcit)  or
maging  within  48  hours  of  initiation  of  treatment,  the  sub-
ect  was  excluded  from  analysis.
All  patients  received  methylprednisolone-valacyclovir,
ssociated  blindedly  to  5  days’  metoclopramide  (30  mg/d)
r  ondansetron  (8  mg/d).  Assessment  was  based  on  early
24—48  hours  after  symptom  onset)  and  1  month  VNG,  ana-
yzing  vestibular  deﬁcit  in  terms  of  slow  horizontal  phase
peed  (◦/s)  and  directional  preponderance  (◦/s)  on  caloric
esting.
Duration  of  hospital  stay  and  time  to  ﬁrst  unassisted
alking  were  also  recorded.
At  end  of  treatment,  the  two  groups  were  compared
or:  patient  age,  early  and  1  month  post-onset  percentage
estibular  deﬁcit  on  the  caloric  test  calibrated  according  to
e  Jonckees,  early  and  1  month  post-onset  directional  pre-
onderance  on  caloric  test  (◦/s),  date  of  ﬁrst  walking  and
ate  of  discharge  home.
Statistical  analysis  comprised  univariate  analysis  (Stu-ent  test)  plus  multivariate  analysis  on  stepwise  logistic
egression,  with  a  threshold  of  0.15  at  each  step.  The  sig-
iﬁcance  threshold  was  systematically  set  at  5%  (Systat  10.2
oftware,  SYSTAT  Inc.).
D
T
iFigure  1  Inclusion  ﬂowchart.
esults
fter  checking  inclusion  criteria,  10  patients  were  included
n  either  arm  and  14  were  excluded  (seven  for  interval  to
reatment  more  than  48  hours,  ﬁve  for  central  signs  on  VNG,
nd  two  for  unilateral  deﬁcit  less  than  25%)  (Fig.  1).
Mean  age  in  group  M  was  48  years  9  months  (range:
1—75  years)  and  in  group  O  61  years  4  months  (range:
3—88  years)  (P  =  0.05  on  Student  test).
Mean  early  vestibular  deﬁcit  was  greater  in  group  M  than
roup  O  (84.38  ±  20.57%  versus  56.53  ±  27.78%;  P  =  0.049
n  Student  test;  Fig.  2).  Mean  early  preponderance  was
0.34  ±  4.26◦/s  and  8.2  ±  5.63◦/s  (P  =  0.40  on  Student  test)
n  groups  M  and  O  respectively  (Fig.  2).
First  unassisted  walking  was  earlier  in  group  O  than
roup  M  (1.25  ±  0.52  versus  2.25  ±  0.89  days;  P  =  0.01on  Stu-
ent  test;  Fig.  3).  Mean  hospital  stay  was  4.5  ±  1.48  and
.88  ±  1.17  days  (P  =  0.03  on  Student  test)  in  groups  M  and  O
espectively  (Fig.  3).
Assessment  at  1  month  found  a  mean  vestibular  deﬁcit
f  63.4  ±  34.30%  in  group  M  and  43  ±  31.25%  in  group  O
non-signiﬁcant  on  Student  t  test:  P  =  0.07;  Fig.  2),  and
ean  preponderance  of  1.74  ±  0.60◦/s  and  1.67  ±  0.63◦/s
P  =  0.40,  Student  t  test),  respectively  (Fig.  2).
Multivariate  analysis  on  linear  logistic  regression  showed
arly  vestibular  deﬁcit  to  correlate  with  early  prepon-
erance  (P  =  0.004)  and  treatment  group  (P  =  0.03).  The
ge  difference  between  treatment  groups  did  not  account
or  the  difference  in  early  vestibular  deﬁcit.  One-month
estibular  deﬁcit  correlated  with  the  early  value  (P  =  0.009),
ut  not  with  treatment  group  or  age.  Hospital  stay  cor-
elated  with  age  and  treatment  group  (P  =  0.01  each),  but
ot  with  early  vestibular  deﬁcit:  advanced  age  and  meto-
lopramide  treatment  were  associated  with  longer  hospital
tay.iscussion
hese  results  indicate  that  ondansetron,  administered  early
n  association  with  corticosteroid  and  antiviral  therapy,  was
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Figure  2  Early  and  1  month  mean  vestibular  deﬁcit  and  directional  preponderance.  Left  column:  caloric  deﬁcit  (above)  and
directional preponderance  (below)  on  early  examination  in  the  metoclopramide  and  ondansetron  groups;  right  column:  the  same
variables at  1  month.  The  only  signiﬁcant  difference  (P  <  0.05)  was  for  early  caloric  deﬁcit.
Figure  3  Date  of  ﬁrst  unassisted  walking  and  mean  hospital  stay  in  the  metoclopramide  and  ondansetron  groups.  Both  time  to
he  o
p
a
r
a
p
p
n
v
m
aﬁrst unassisted  walking  and  total  hospital  stay  were  shorter  in  t
more  effective  than  associated  metoclopramide  in  reducing
hospital  stay  in  vestibular  neuritis  patients.
The  explanation  of  this  effect  is  two-fold.  On  one  hand,
it  may  lie  in  improved  tolerance  for  the  vegetative  signs
(nausea  and  vomiting)  associated  with  vertigo,  against  which
ondansetron  is  more  effective  than  metoclopramide  [7].
On  the  other  hand,  ondansetron  may  also  act  on  the
early  vestibular  deﬁcit  found  on  the  ﬁrst  VNG  examina-
tion.
Early  vestibular  deﬁcit  was  lower  in  group  O  than  group
M.  The  5-HT3  antagonist  effect  of  ondansetron  may  play  a
role  in  vestibular  synapse  neuromodulation,  limiting  possi-
ble  excitotoxicity  secondary  to  excessive  glutamate  release,
as  seen  in  the  cochlea  following  acoustic  trauma  and  in
the  vestibule  following  aminoside  [8,9]  or  AMPA  receptor
antagonist  treatment  [10].
r
v
dndansetron  group  (P  <  0.05).
It has  been  shown  in  stroke  models  that  5-HT3  receptors
lay  a  role  in  aggravating  post-infarction  toxic  lesions  [6];
s  they  are  expressed  in  animals  in  Scarpa’s  ganglion  neu-
ons  and  medial  brainstem  vestibular  nuclei  [5],  the  question
rises  as  to  their  role  in  vestibular  physiology.
These  receptors  are  very  probably  activated  under
hysiological  conditions,  given  their  presence  in  the  area
ostrema  and  solitary  tract,  which  are  areas  involved  in  the
ausea-vomiting  reﬂex  [11]  and  which  project  toward  the
estibular  nuclei  [12,13].  Their  role,  however,  can  hardly  be
ore  than  one  of  modulation,  since  clinical  use  of  5-HT3
ntagonists  induces  neither  vertigo  nor  astasia.
These  arguments  are  particularly  supported  by  several
eports  of  the  interest  of  ondansetron  in  the  treatment  of
ertigo  and  astasia  following  cerebral  trauma  and  brainstem
amage  related  to  multiple  sclerosis  [14,15].
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For  neuroprotective  purposes,  very  early  application  is
robably  needed  for  a  clinical  effect  to  be  induced.  Here
ies  the  main  limitation  of  the  present  study.  There  was  a
roup  difference  in  early  vestibular  deﬁcit:  but,  when  this
as  measured,  the  patients  were  already  receiving  meto-
lopramide  or  ondansetron,  and  it  is  impossible  to  know,
or  obvious  reasons  of  examination  tolerance,  whether  the
wo  groups  had  comparable  deﬁcits  before  initiation  of
reatment.  Only  a  larger  series  could  answer  this  ques-
ion.
At  all  events,  ondansetron  does  not  impair  the  capa-
ity  for  central  compensation,  as  seen  in  the  absence  of  any
ifference  in  directional  preponderance  between  the  two
roups,  with  scores  less  than  2◦/s  in  both.
The  medium-term  effect  of  ondansetron  is  harder  to
ssess.  While  there  was  a  notable,  if  non-signiﬁcant,  group
ifference  at  1  month,  this  seemed  purely  related  to  early
eﬁcit  values:  if  the  early  deﬁcit  was  indeed  related  to
reatment,  it  may  be  supposed  that  ondansetron,  by  its
cute-phase  effect,  limits  the  worsening  or  promotes  reco-
ery  of  the  early  deﬁcit.
These  hypotheses  thus  remain  to  be  conﬁrmed,  and  dose-
esponse  studies  on  larger  series  and  animal  models  of
cute  vestibular  deﬁcit  will  be  needed  to  determine  the
ction  mechanism  of  5-HT3  antagonists  in  vestibular  neu-
itis.
onclusion
he  results  of  the  present  pilot  study  suggest  that
ndansetron  administered  in  the  acute-phase  of  vestibu-
ar  neuritis  in  association  with  corticosteroid  and  antiviral
herapy  reduces  vestibular  deﬁcit  and  hospital  stay  in  com-
arison  with  reference  anti-H1  antiemetic  treatment  in  the
ame  association.  Speciﬁcity  and  action  mechanism,  how-
ver,  remain  unknown  and  should  be  explored  in  animal
odels  and  a  larger  series  in  order  to  determine  whether
he  present  ﬁndings  can  be  generalized  in  the  management
f  this  pathology.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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